A U.S. jury on Monday determined that Takeda (TAK) Pharmaceutical caused pharmacies, insurers, retailers, and others to sustain roughly $885M in damages by postponing the release of a generic version of its anti-constipation drug Amitiza through anticompetitive means, Reuters’ Nate Raymond reports.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAK:
- Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says
- Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says
- Trump Trade: Trump says Xi agreed to buy 200 jets from Boeing
- Justice Department announces $13.67M civil settlement with Takeda
- These Are the Stocks Reporting Earnings Today – May 13, 2026